Is intramuscular administration appropriate for rocuronium or vecuronium?

Intramuscular Administration of Rocuronium or Vecuronium

Neither rocuronium nor vecuronium should be administered intramuscularly in routine clinical practice—both are FDA-approved for intravenous use only. 1, 2

FDA-Approved Routes of Administration

The FDA drug labels are unequivocal:

• Rocuronium: "for intravenous use only" 1
• Vecuronium: "for intravenous use only" 2

Both medications are explicitly labeled as intravenous agents, and intramuscular administration is not an approved route.

Research Evidence on IM Rocuronium

While research has explored IM rocuronium in pediatric populations, the results demonstrate significant limitations:

In Infants and Children

• IM rocuronium does NOT consistently provide adequate intubating conditions 3
• A multicenter study found inadequate intubation conditions in a high percentage of patients:
  • Only 9 of 16 infants had adequate conditions at 3.5 minutes (not the intended 2.5 minutes)
  • Only 10 of 17 children had adequate conditions at 4 minutes (not the intended 3 minutes)
  • The study concluded IM rocuronium "is not an adequate alternative to intramuscular succinylcholine when rapid intubation is necessary" 3

Dosing and Timing Issues

• Deltoid injections of 1 mg/kg (infants) or 1.8 mg/kg (children) were studied 4
• Onset to adequate intubation: 2.5 minutes in infants, 3 minutes in children 4
• Duration of action is excessively prolonged: 57±13 minutes in infants and 70±23 minutes in children—far too long for most clinical scenarios 4
• Quadriceps injections showed even slower, less reliable onset 4

Clinical Guideline Context

The 2020 Anaesthesia guidelines on muscle relaxants make no mention of intramuscular administration for either agent, focusing exclusively on IV dosing and monitoring strategies 5. For rapid sequence induction in children, the guidelines recommend suxamethonium as first-line, with rocuronium as an alternative—but only via IV route 5.

Critical Pitfalls

1. Medication errors: The FDA explicitly warns that "accidental administration of neuromuscular blocking agents may be fatal" 1
2. Unpredictable onset: IM administration produces inconsistent timing and depth of blockade
3. Prolonged paralysis: The large IM doses required produce excessively long durations of action
4. Lack of monitoring: Without IV access, you cannot titrate or reverse effectively
5. No reversal access: If complications occur, you cannot rapidly administer sugammadex or neostigmine

The Bottom Line

Use intravenous rocuronium or vecuronium exclusively. If IV access cannot be established and neuromuscular blockade is urgently needed, IM succinylcholine (where not contraindicated) remains the only validated intramuscular neuromuscular blocker. The research on IM rocuronium demonstrates it is unreliable and produces excessive duration of paralysis, making it unsuitable for clinical use 3, 4.